Genetic induction of PTEN expression in combination of with the EGFR inhibitor gefitinib synergistically suppresses PTEN-deficient and EGFR-overexpressing BLBC tumor growth and causes tumor regression [18]. This evidence concerns the gene EGFR and neoplasm.